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Abstract
Background: Metastatic brain cancers are the most common intracranial tumor and occur in about 15% of all cancer 
patients. In up to 10% of these patients, the primary tumor tissue remains unknown, even after a time consuming and 
costly workup. The Pathwork® Tissue of Origin Test (Pathwork Diagnostics, Redwood City, CA, USA) is a gene expression 
test to aid in the diagnosis of metastatic, poorly differentiated and undifferentiated tumors. It measures the expression 
pattern of 1,550 genes in these tumors and compares it to the expression pattern of a panel of 15 known tumor types. 
The purpose of this study was to evaluate the performance of the Tissue of Origin Test in the diagnosis of primary sites 
for metastatic brain cancer patients.
Methods: Fifteen fresh-frozen metastatic brain tumor specimens of known origins met specimen requirements. These 
specimens were entered into the study and processed using the Tissue of Origin Test. Results were compared to the 
known primary site and the agreement between the two results was assessed.
Results: Fourteen of the fifteen specimens produced microarray data files that passed all quality metrics. One 
originated from a tissue type that was off-panel. Among the remaining 13 cases, the Tissue of Origin Test accurately 
predicted the available diagnosis in 12/13 (92.3%) cases.
Discussion: This study demonstrates the accuracy of the Tissue of Origin Test when applied to predict the tissue of 
origin of metastatic brain tumors. This test could be a very useful tool for pathologists as they classify metastatic brain 
cancers.
Background
Metastatic tumors to the brain are the most common
central nervous system (CNS) neoplasm and occur in
about 15% of all cancer patients. In an adult, these tumors
originate most frequently from lung, breast, skin, kidney
and colon [1]. In up to 10% of patients, no clear primary
site can be determined despite an intensive clinical evalu-
ation [2,3]. Current treatment regimens for these patients
with unknown primaries include surgery, radiation and
chemotherapy [4,5]. Despite these treatments, the sur-
vival rates of patients with brain metastases remain low.
A recent retrospective review of 740 patients with brain
metastases of all tissue types reported actuarial survival
rates of 8.1% at 2 years and 2.4% at 5 years [6].
The last decade has seen the emergence of a number of
markers of immunohistochemistry (IHC) that have been
helpful in indicating the origin of common metastatic
tumors to the brain [7,8]. Workup of an immunohis-
tochemical signature requires selection and use of a large
number of antibodies and knowledge of their reactivities
(and cross-reactivities) to different cancer types. A
recently proposed algorithm for immunohistochemical
evaluation of the common types of brain metastases rec-
ommends the use of 18 antibodies to distinguish 10 can-
cer types [7]. Immunohistochemical markers with a high
degree of sensitivity and that are also highly specific for a
single primary site are uncommon. In addition, interpre-
tation of immunohistochemical stains is user-dependent
and requires subjective interpretation. Even after a rigor-
ous workup, success rates at identifying primary tumor
sites are not optimal [9]. A meta-analysis of four studies
in which pathologists were blinded to the knowledge of
the primary site showed that even an extensive IHC
workup correctly identified the primary site for only 66%
of all metastatic specimens [9]. Additional diagnostic
approaches are required to complement more traditional
IHC analysis.
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microarrays or real-time reverse transcription poly-
merase chain reaction (RT-PCR) have been developed to
identify the tissue of origin of metastatic cancers [10,11].
Among these, microarray-based assays have the advan-
tage of simultaneously evaluating the gene expression
pattern of thousands of genes. The information generated
is mined using multigene classifiers that predict the tissue
of origin. The Pathwork® Tissue of Origin Test (Pathwork
Diagnostics, Redwood City, CA, USA) for frozen speci-
mens uses microarray technology to measure the gene
expression pattern, comprising 1550 genes, of a tumor
with an uncertain origin and compares it to expression
patterns of a panel of 15 known tumor types. The tissue
types represented are: bladder, breast, colorectal, gastric,
hepatocellular, kidney, non-small cell lung, ovarian, pan-
creatic, prostate, thyroid, melanoma, testicular germ cell,
non-Hodgkin's lymphoma, and sarcoma. This panel rep-
resents approximately 90 percent of all solid tumors and
58 morphologies overall. In validation studies, the Tissue
of Origin Test had an accuracy of 87.8% in a set of 547
frozen specimens and delivered reproducible results
(93.8% concordance) in four different laboratory settings
[10,12].
The purpose of this study was to evaluate the perfor-
mance of the Pathwork Tissue of Origin Test in identify-
ing the primary site for metastatic brain cancer patients.
Fifteen cases of metastatic brain cancers of known origins
were processed through the Tissue of Origin Test, and
predicted the accurate tissue of origin in 92.3% of cases
that met specimen entry criteria. These results show that
the Tissue of Origin Test is a useful diagnostic tool to aid
physicians treating metastatic brain cancer patients.
Methods
Tumor Specimens
Tumor specimens that met the following criteria were
entered into the study: excisional biopsies of brain metas-
tases, fresh-frozen (100 mg) samples available for analy-
sis, sample contained at least 60% tumor and < 20%
necrosis and the primary site of the tumor was known.
Sixteen fresh-frozen brain metastases were obtained
from the UCSF Neurological Surgery Tissue Bank using
protocols approved by the UCSF Committee of Human
Research. One additional frozen brain metastasis tumor
specimen was obtained from Cytomyx (Rockville, MD).
In addition, microarray data files for seven frozen brain
metastases were obtained from Gene Logic, Inc. (Gaith-
ersburg, MD) and one from Gene Expression Omnibus
(GEO; Accession number GSM76622). When available,
Hematoxylin and Eosin (H&E) sections adjacent to the
tumor sample were reviewed by a pathologist to deter-
mine the percentage of tumor cells and necrosis. In all
cases, the primary tissue site of the brain metastasis was
known.
RNA Extraction, Target Preparation, and Microarray 
Processing
Specimens were processed as described earlier [10,12].
Total RNA was extracted using the RNeasy Midi kits
(Qiagen Inc., Valencia, CA) following manufacturer-rec-
ommended protocols and as described earlier [12]. Total
RNA concentration was assessed by spectrophotometry
(OD 260 nm), and the purity was judged by the ratio of
absorbance at 260 nm to 280 nm (A260/A280). Biotin-
labeled cRNA was synthesized using GeneChip expres-
sion assay reagents and protocols (Affymetrix, Inc, Santa
Clara, CA), and the samples were hybridized to the Path-
work Diagnostics Pathchip using commercially available
reagent kits and protocols (Affymetrix, Inc., Santa Clara,
CA). The arrays were scanned using the Affymetrix
GCS3000 Scanner. The resulting raw intensity data files
(CEL files) were processed at Pathwork Diagnostics for
automated analysis and report generation. The CEL files
contain raw data on RNA expression in each tumor. Only
CEL file that have greater than a minimum threshold of
overall signal of 20 are used for further analysis. The Tis-
sue of Origin Test utilizes the expression levels of 1550
Table 1: Patient Demographics.
Primary Site (n = 15)







Head & Neck 1
Gastric 1
Kidney 1
Patient Age Years (n = 6)*
Median 41
Range 21-56




* Only 6/15 cases had information on age available
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types as described earlier [10].
Results
Tumor Specimens and Quality Control
The 25 brain metastases specimens were reviewed for eli-
gibility in the study. Fifteen specimens met all criteria and
were entered into the study. Patient demographics for
these 15 specimens are summarized in Table 1. In all
cases, the biopsy site was brain. The most common pri-
mary sites were breast and lymphoma (3/15 cases each),
followed by lung and melanoma (2/15 cases each). The
most common specimen morphology was adenocarci-
noma and all morphologies were consistent with the
available diagnoses (Table 2). The majority (77.8%) of the
brain metastases were located in the cerebral hemi-
spheres while a smaller number of cases (22.2%) were
located in the cerebellum (Table 2).
Figure 1 Sample Tissue of Origin Test Report. The Tissue of Origin Test report for specimen with case ID K in this study is shown as a sample report. 
The report presents similarity scores to each of the 15 tissue types included in the Tissue of Origin Test panel. A similarity score of 90.6 indicates a high 
confidence that this specimen is a breast cancer metastasis to the brain. Also, the Tissue of Origin Test excluded 13 tissue types (those with similarity 
scores less than or equal to 5) as the likely tissue origins for this specimen.
Table 2: Clinical Characteristics of Brain Metastases Cases.
Case ID Available Diagnosis Specimen Morphology Location within Brain
A Sarcoma Sarcoma Temporal-Parietal
B Kidney Renal cell carcinoma Temporal-Occipital
C Melanoma Malignant melanoma Parietal Lobe
D Melanoma Malignant melanoma Frontal Lobe
E Breast N/A Cerebellum
F Breast Carcinoma N/A
G Lung Poorly differentiated 
carcinoma
Frontal Lobe
H Lymphoma Diffuse large B-cell lymphoma Temporal Lobe
I Lymphoma Diffuse large B-cell lymphoma N/A
J Colon Adenocarcinoma Temporal Lobe
K Breast Adenocarcinoma Cerebellum
L Head & Neck Squamous Cell Carcinoma N/A
M Gastric Adenocarcinoma N/A
N Lung Adenocarcinoma N/A
O Lymphoma Diffuse large B-cell lymphoma N/A
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The Tissue of Origin Test produces a similarity score for
each of the 15 tissue types included in the Tissue of Ori-
gin Test panel. A sample report (specimen with Case ID
K in this study) is shown in Figure 1. The similarity score
is a measure of the similarity of the gene expression pro-
file of the specimen to the profile of the indicated tissue,
ranging from 0 (very low similarity) to 100 (very high
similarity). Similarity scores for all 15 tissues sum to 100.
In addition, any tissue with a similarity score less than or
equal to 5 has a 99.8% probability of not being on the tis-
sue of origin. Thus, the Tissue of Origin Test can be used
to exclude, or rule out, origins from specific tissues on the
Test panel.
Fourteen of the 15 specimens entered into the study
were processed successfully to yield qualified data files
and Tissue of Origin Test results (Table 3, complete
results in Additional File 1). The specimen that did not
yield a qualified data file had low overall signal intensity.
Another specimen was head and neck which is not one of
the 15 tissues represented on the Tissue of Origin Test
panel. For the thirteen on-panel specimens, the Tissue of
Origin Test accurately predicted the primary in 92.3% of
the cases. Overall, including the off-panel specimen, the
Tissue of Origin Test accurately predicted the primary in
12/14 (85.7%). The one non-agreement between the Tis-
sue of Origin Test result (ovarian carcinoma) and the
clinically available diagnosis (lung carcinoma) was seen in
a female that was histopathologically diagnosed as a met-
astatic adenocarcinoma.
In addition to the predicted primary (tissue with the
highest Similarity Score), each test result ruled out as a
primary site (Similarity Scores < 5) an average of 13 of the
15 tissues on the panel. The distribution of the available
diagnoses and Tissue of Origin Test results by tissue and a
confusion matrix of these data are shown in Figure 2.
Available diagnoses for specimens entered into the study
represented nine independent tissues (Figure 2A). The
Tissue of Origin Test Result for the off-panel case of
squamous cell carcinoma of the head and neck was lung.
Discussion
The Pathwork Tissue of Origin Test showed a high degree
of agreement with the clinically available diagnosis, accu-
rately identifying the primary site for 92.3% of the metas-
tases to brain from primary sites on the Tissue of Origin
panel and 86.7% overall (including the off-panel head and
neck carcinoma). This rate of agreement is quite compa-
rable to the percent agreement of 87.8% obtained during
the clinical validation of the Tissue of Origin Test [10]
and is superior to the 66% agreement seen in similar
blinded studies in which a pathologist uses immunohis-
tochemistry to identify the primary [9]. In addition to
providing information about the most likely primary site,
each Test also provided information that definitively
ruled out an average of 13 tissues as sites of origin.
The cases in this study were not selected for having pri-
mary sites on the Tissue of Origin Test panel. Nonethe-
less, 93% of the specimens' primary sites were available
on the Tissue of Origin Test panel. For the off-panel spec-
imen, the Test generated 13 tissue rule-outs. The Tissue















E Pass Breast Breast 90.6 Yes
F Pass Breast Breast 81 Yes
K Pass Breast Breast 90.5 Yes
H Pass Lymphoma Lymphoma 90.4 Yes
I Pass Lymphoma Lymphoma 87.7 Yes
O Pass Lymphoma Lymphoma 94.4 Yes
G Pass Lung Lung 62.6 Yes
N Pass Lung Ovarian 89.4 No
C Pass Melanoma Melanoma 77 Yes
D Pass Melanoma Melanoma 75.9 Yes
J Pass Colon Colon 82.4 Yes
M Pass Gastric Gastric 35 Yes
A Pass Sarcoma Sarcoma 65.2 Yes
L Pass Head & Neck Lung 77.3 Off-Panel
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expected distribution of primary sites for the tumors
most commonly metastasizing to brain [1].
Currently, a version of the test has become available
that works with formalin-fixed paraffin-embedded
(FFPE) specimens [13]. The ability to use FFPE enhances
the clinical utility of the Tissue of Origin Test since FFPE
is the more commonly available clinical material. While
the method of processing the total RNA and classification
algorithm used are different in the frozen and FFPE ver-
sions of the Tissue of Origin Test, they both use microar-
ray expression data and multigene classifiers to
distinguish between the same 15 tissue types described in
this study. The FFPE Test output, similar to the frozen
Test, is 15 similarity scores that range from 0 (very low
similarity) to 100 (very high similarity). Importantly, clin-
ical validation studies have shown that performance of
the FFPE Test had an accuracy of 88.5% in a set of 462
FFPE specimens which is equivalent to the frozen Test
[10,13].
A large number of screened samples were not eligible
for entry into the study because they contained extensive
necrosis. The validation studies for the Tissue of Origin
Test did not include samples with necrosis > 20%. Tumor
Figure 2 Distribution of the available diagnosis and the Tissue of Origin Test result by tissue type. Pie charts (A) and a confusion matrix (B) 
were used to compare the available diagnosis with the Tissue of Origin Test results. Among the cases that were on-panel, the Tissue of Origin Test had 
a 92.3% (12/13) agreement with the available diagnosis. The Tissue of Origin Test Result for the off-panel case of squamous cell carcinoma of the head 
and neck was lung. Abbreviations are BR = Breast, CO = Colon, GA = Gastric, LU = Lung, LY = Lymphoma, ME = Melanoma, SC = Sarcoma, OV = Ovarian.
Result\Specimen
# of 
Specimens BR CO GA LU LY ME SC OV 
BR 3 3        
CO 1  1       
GA 1   1      
LU 2    1    1 
LY 3     3    
ME 2      2   
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recognizable tumor tissue only at the periphery of the
lesion and around blood vessels. Tissue macrodissection
to remove necrotic tissue performed by a trained pathol-
ogist might be used successfully with the Tissue of Origin
Test for highly necrotic samples. The FFPE version of the
Tissue of Origin Test can be used with specimens con-
taining up to 40% necrosis (minimum 60% tumor tissue)
making it more useful in clinical practice for brain
tumors. Additionally, tumor punches of FFPE tissue
blocks can be performed to select non-necrotic tumor
tissue for the Tissue of Origin Test.
Our study shows that the Tissue of Origin Test is a use-
ful diagnostic tool for brain metastases and can serve as a
tool for neuropathologists as they classify metastatic
brain cancers. It is expected that improved accuracy in
the diagnosis of the primary sites for metastatic brain
cancer will aid in selecting further diagnostic tests and
optimal therapy. Not only would it guide the clinical
workup to locate the primary tumor but it would allow
oncologists to treat these patients with more specific tar-
geted therapies. Several cancers that commonly metasta-
size to the brain such as breast, ovarian and small cell
lung carcinomas are highly responsive to current thera-
pies and an accurate diagnosis would be of considerable
benefit to these patients. Accurate identification of the
primary site could eventually lead to improved clinical
outcomes. It has been shown that identifying colon as the
primary site for carcinoma of unknown primary (CUP)
patients results in improved clinical outcome [14,15].
These CUP patients had better response to colon-cancer
specific treatment regimens than they did to empiric
CUP therapy with paclitaxel and carboplatin-based regi-
mens.
Conclusions
The Pathwork Tissue of Origin Test has high accuracy in
identifying the primary site for brain metastases cases.
This test could be a valuable tool for pathologists as they
classify metastatic brain cancers potentially resulting in
improved clinical management of these patients.
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Additional file 1 Tissue of Origin Test Results with all 15 Similarity 
Scores for the Brain Metastases Cases. This table contains complete Tis-
sue of Origin Test results, including all 15 similarity scores, for the 14 brain 
metastases cases in this study. The highest similarity score for each case is 
highlighted and represents the identified Tissue of Origin for that case.
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